POTE ankyrin domain family member EGenealiases: A26C1 · A26C1A · CT104.2 · POTE-2 · POTE2 · POTE2gamma
Q-omics provides the consensus-scored POTEE profile across patient tissues and cancer cell-line models. POTEE expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, POTEE is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, POTEE RNA expression shows 13,576 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, HNSC, and THYM as cancer lineages where POTEE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEE survival associations across molecular data types. POTEE RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEE RNA expression–survival associations across cancer types. High POTEE expression shows unfavorable associations in KICH, LUSC, MESO, OV, THCA and LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for POTEE RNA expression.
This table summarizes POTEE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for POTEE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEE shows higher tumor expression in HNSC, LUSC, BRCA, UCEC, PRAD and COAD. The HNSC box plot shows higher POTEE RNA expression in tumor versus normal tissue (log2 FC = +0.088, t-test p = .001).
This table shows molecular features associated with POTEE in patient tissues and cancer cell lines. In patient samples, POTEE shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
